
HeartBeam Outlines Next Steps After FDA Decision on 12-Lead ECG Synthesis Software Application
HeartBeam Outlines Comprehensive Regulatory Strategy Following FDA’s Not Substantially Equivalent Determination for 12-Lead ECG Synthesis Software HeartBeam, Inc., a medical technology company pioneering innovative cardiac diagnostic solutions, has provided a detailed update on its regulatory pathway after receiving a Not…












